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Abstract
Background: Blepharospasm and hemifacial spasm are debilitating conditions that significantly impact on patient
quality of life. Cyclical treatment with botulinum toxin injections offers temporary relief, but the duration of treatment
efficacy is variable. The standard model of patient care defines routine fixed-time based scheduled treatment cycles
which may lead to unnecessarily frequent treatment for some patients and experience of distressing symptoms in
others, if symptoms return before the scheduled follow-up period.
Methods/Design: A randomised controlled trial will compare a patient-initiated model of care, where patients
determine botulinum toxin treatment timing, to the standard model of care in which care is scheduled by the clinical
team. A sample of 266 patients with blepharospasm or hemifacial spasm will be recruited from Moorfields Eye Hospital
(MEH), London. The trial will be accompanied by a mixed-methods evaluation of acceptability of the new service.
Patients who meet eligibility criteria will be assessed at baseline and those in the intervention group will be provided
with instructions on how to book their own treatment appointments. Patients in both groups will be followed up 3
and 9 months into the trial and all patients will be returned to usual care after 9 months to meet safety protocols.
Primary outcome measures include disease severity (questionnaire), functional disability (questionnaire) and patient
satisfaction with care (questionnaire). Secondary outcomes include disease-specific quality of life (questionnaire), mood
(questionnaire), illness and treatment perceptions (questionnaire and semi-structured interviews), economic impact
(questionnaire) and acceptability (questionnaire and semi-structured interviews).
Discussion: This trial will assess the effectiveness and cost-effectiveness of a patient-led care model for botulinum
toxin therapy. If the new model is shown to be effective in reducing distress and disability in these populations and
is found to be acceptable to patients, whilst being cost-effective, this will have significant implications for service
organisation across the NHS.
Trial registration: UK Clinical Research Network (UKCRN) Portfolio 18660. Clinicaltrials.gov ID NCT02577224 (registered
29 October 2015)
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Background
Blepharospasm is a dystonia described by sustained,
forced, involuntary closure of both eyelids, caused by
muscle contraction. Hemifacial spasm occurs on one
side of the face and can result in complete closure of
one eye, and spasms across the cheek, face and neck.
Hemifacial spasm, as its name implies, is unilateral,
whereas blepharospasm always affects both eyes. Bleph-
arospasm and hemifacial spasm are debilitating condi-
tions, which carry the risk of functional blindness and
can lead to appearance concerns, social embarrassment
and isolation, depression and poor quality of life [1–3].
Botulinum toxin is the treatment used in standard care
to alleviate spasms, but by their nature result in a cyc-
lical pattern of relief and aggravation as the toxin wears
off [4] and hence patients return for repeated injections.
A recent systematic review indicated that the patient- re-
ported benefits of botulinum toxin in blepharospasm
ranged from no improvement to 96 % of patients report-
ing a significant relief in symptoms [5]. Evidence for the
duration of benefit provided by repeated treatment is
also markedly inconsistent [5]. Although the definition
of benefit did differ between studies in this review, much
of the inconsistency between studies remains unresolved.
Despite this, a dosing interval of 3- to 4-monthly injec-
tions is typical for many different dystonias across the
UK. However, the variation in response to this treatment
may mean that some people are left experiencing debili-
tating symptoms until their next scheduled appointment
and some are being seen more often than their symp-
toms would deem necessary. It would potentially be
more useful, therefore, to explore alternative models of
care based more closely on symptoms.
Patient-centred care is at the forefront of the NHS [6,
7] reflecting the shift away from the paternalistic model
of healthcare. Patients are now encouraged to take a
more active role in knowing and managing their health,
and this is especially important in conditions such as
dystonia where the reality of living with the condition is
demanding. As a result patient-led healthcare services
are becoming increasingly more common [8] and have
the potential to address the inconsistencies found in the
current botulinum toxin treatment regimen.
Studies of patient-initiated services, where the patient
rather than healthcare professional initiates treatment
and care, have shown promise. These services provide
patients with information on when and how to access
services, rather than having regular time-based sched-
uled appointments. A systematic review conducted by
Whear et al. [8] synthesised the evidence for this model
of care across three conditions: irritable bowel disease,
breast cancer and rheumatoid arthritis. Overall, there
were few differences in psychological or health-related
quality of life outcomes between those initiating their
own outpatient follow-up appointments compared to
standard care, despite in many cases patients having less
contact with healthcare professionals. Patient and clin-
ician satisfaction were significantly greater in the
patient-initiated services compared to regular appoint-
ment scheduling. Another more recent trial has also
found significant reductions in healthcare utilisation
without compromising clinical or psychosocial well-
being [9].
Adopting a patient-led model of care has the potential
to reduce morbidity and disability in patients with a
short-term response to botulinum toxin. Conversely, this
may also reduce unnecessary hospital visits and treat-
ment for patients with a longer-term response. There is
currently one patient-initiated, nurse-led botulinum
toxin clinic running in the UK for patients with bleph-
arospasm or hemifacial spasm [10], but is yet to be eval-
uated in comparison to usual care. Due to the variable
nature of the duration of response to treatment, bleph-
arospasm and hemifacial spasm are appropriate condi-
tions in which to evaluate a service of this nature. This
study, therefore, provides a unique opportunity to em-
power patients with dystonia to take control of their
treatment scheduling and optimise the effects of botu-
linum toxin, by allowing them to seek treatment when
they feel it is necessary rather than it being dictated by
the clinical team.
The primary aims of this randomised controlled trial
(RCT) are to: (1) investigate the effectiveness of a
patient-led model for botulinum toxin treatment in
maintaining a more stable pattern of disease severity and
disability in patients with hemifacial spasm and bleph-
arospasm in comparison to standard care, and (2) assess
patient satisfaction with the new treatment model com-
pared to standard care. The secondary aims are the as-
sessment the impact of the service on psychosocial
outcomes, including quality of life, illness perceptions,
mood, acceptability and cost-effectiveness.
Methods
Study design
This study will be mixed methods adopting a concurrent
embedded strategy [11], whereby a qualitative study will
be embedded within a larger single-masked RCT, with
the RCT as the dominant component. This design will
provide information on effectiveness and also an in-
depth assessment of the patient experience. The RCT
will be a parallel-group, explanatory, superiority RCT
designed to assess the effectiveness of a patient-initiated
botulinum toxin service compared to usual care. Semi-
structured interviews will be conducted with a sample of
intervention participants in order to assess acceptability
of the service.
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Randomisation
Randomisation (1:1) will be undertaken by a central ran-
domisation service by the data management team at
Moorfields Eye Hospital (MEH) in order to ensure the
research fellow collecting and analysing the data is
blinded to group allocation. Participants will be rando-
mised to receive either treatment as usual or patient-
initiated follow-up appointments. Randomly permutated
blocks of varying sizes will be employed to ensure bal-
ance between treatment groups. Due to the nature of
the nurse-led botulinum toxin clinic it will not be pos-
sible to blind the treating healthcare professionals from
group allocation. The trial co-ordinator will staff the
telephone line that participants in the intervention
group will use to book their appointments and, as such,
the trial co-ordinator will not be blinded to group
allocation.
Blinding
Due to the nature of the study, participants cannot be
blinded to group allocation. The treating healthcare pro-
fessionals will also not be masked. The research fellow
responsible for entering data into the database and the
statistician conducting data analysis will be blinded to
participant allocation. All other members of the research
team will be blinded to allocation throughout the study,
prior to un-blinding at the end of analysis.
Setting
The outpatient nurse-led botulinum toxin clinic at
MEH.
Inclusion criteria
Patients aged 18 years or over who have received a
consultant-led diagnosis of hemifacial spasm or bleph-
arospasm will be invited to take part in the trial. Eligible
patients need to be on a stable dose of botulinum toxin
treatment, defined as receiving toxin treatment over two
previous cycles and free from side effects. Potential side
effects of botulinum toxin treatment include ptosis,
double or blurred vision, and foreign body sensations.
Patients must possess the capacity to give informed con-
sent to participate in the study, as judged by the special-
ist research nurse leading the clinic.
Exclusion criteria
Patients will be excluded if they have significant co-
morbidities (i.e. their predominant treatment is for an-
other illness) and/or they are unable to communicate
fluently in written and/or spoken English, to complete
study measures.
Intervention
Participants randomised to the intervention group will
initiate their own treatment during the trial period
(9 months). They will be given information about when
and how to initiate an appointment in the nurse-led
botulinum toxin clinic, in a leaflet sent to them by a trial
co-ordinator after randomisation. Participants will be
asked to contact the service when they feel their symp-
toms are returning at a sufficient level for them to seek
medical help. Contact details for the service will also be
provided along with information on how quickly an ap-
pointment will be made, with whom, and the procedure
in the case of an emergency. Receipt of the leaflet will be
followed by a telephone call from one of the research
team to answer any questions participants may have.
When participants in the intervention group contact the
service to book an appointment they will be triaged by
the trial co-ordinator. All patients with an activity score
of 1 or above on the Jankovic Rating Scale (JRS; [12])
will be booked in to the next available slot within the
twice-weekly nurse-led outpatient clinics, estimated
within a 2-week period from the initial call. There will
be no upper limit for the number of times participants
in the intervention group can initiate an appointment.
However, participants will be advised to wait 2 weeks
after botulinum toxin treatment as this is the time it
takes to reach effectiveness. It is, therefore, estimated
that participants would not return to the clinic within 3
to 4 weeks of their previous appointment. All partici-
pants will be given an appointment at 9 months to meet
safety criteria for any patients who do not seek an ap-
pointment during their participation in the trial.
Control group
Participants in the control group will receive usual care.
This consists of scheduled appointments in the nurse-
led outpatient botulinum toxin clinic, usually every
3 months.
Outcomes
Participants will be in the trial for 9 months. An initial
baseline assessment will be taken by a research fellow
prior to randomisation; this will include the full range of
measures. Self-report measures will be taken again at 3-
and 9-month follow-ups.
At baseline, demographic information will be collected
using self-report measures including: date of birth, gen-
der, marital status, ethnicity, postcode, number of years
of schooling, highest completed level of education and
further education. Data will also be collected from the
patients’ medical notes on diagnosis, year of diagnosis,
duration of botulinum toxin treatment, number of previ-
ous cycles, frequency of previous cycles, last dose, and
co-morbidities. The total number of botulinum toxin
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injections and dosage received by the patient across the
trial period will be collected.
Primary outcome measures
Disease severity and symptoms Disease severity and
frequency of symptoms will be assessed using the JRS
[12], a clinician-reported measure that consists of two
subscales measuring symptom severity and frequency in-
dependently. A 2-point improvement in the JRS sum
score is considered a clinically relevant improvement
[13]. However, these criteria are only relevant for pa-
tients whose baseline scores are >2 on the JRS [13]. For
patients with hemifacial spasm an additional rating scale
for severity and frequency of cheek involvement will be
included in the JRS, as suggested by Wabbels and Rog-
genkämper [14].
Functional disability The Blepharospasm Disability
Index (BSDI)© [15, 16] is a patient self-report measure
that asks about six daily activities: reading, driving a ve-
hicle, watching TV, shopping, walking and doing every-
day activities. The measure is also recommended for use
in hemifacial spasm [14]. Each activity is rated on a scale
from 0 = no impairment to 4 = no longer possible due to
my illness, and a ‘not applicable’ option is also available.
The scoring system is a mean item score, calculated by
dividing the sum score by the number of applicable
items. Sum scores, therefore, range from 0 to 4 with
higher scores indicating greater disability. A 0.7-point
improvement in the BSDI© mean item score is consid-
ered a clinically relevant improvement [13]. However,
this criteria is only relevant for patients whose baseline
scores are >0.7 [13]. The measure possesses good con-
vergent validity with the JRS, good internal consistency
(Cronbach’s alpha = 0.88) and adequate test-retest reli-
ability [13].
Patient satisfaction Patient satisfaction will be mea-
sured using the eight-item Client Satisfaction Question-
naire (CSQ; [17]). Responses to each of these eight items
range on a Likert scale from 1 to 4, each item has differ-
ent weighted responses and patients will be instructed to
answer in response to the care they receive in the nurse-
led botulinum toxin clinic. Items include ‘How would
you rate the overall quality of the service your received?’.
Scale scores are a sum of the eight items and range from
8 to 32, with higher scores indicating greater satisfaction.
The scale has good internal reliability, with a Cronbach’s
alpha of 0.93 and good construct validity [18].
Secondary outcome measures
Quality of life Quality of life will be measured using the
Craniocervical Dystonia Questionnaire (CDQ-24; [19]),
which was developed and validated in patients with
blepharospasm and has also been used with success in
patients with hemifacial spasm [20]. This 24-item meas-
ure assesses quality of life across five domains: stigma,
emotional well-being, pain, activities of daily living and
social/family life. Each item consists of five statements
representing increasing severity of impairment and is
scored from 0 to 4. In order to obtain comparable scores
for the individual subscales, raw sub-scores (= sum of
the individual item score) are linearly transformed to a
0–100 scale, where a score of 0 indicates the best and a
score of 100 the worst possible quality of life. The meas-
ure has been found to possess good internal consistency
with Cronbach’s alphas ranging from 0.77 to 0.89, good
construct validity when compared who the Short Form
36 (SF-36), good discriminant validity and test-retest re-
liability [20].
Mood The Hospital Anxiety and Depression Scale
(HADS; [21]) will be used to assess mood. The HADS is
a 14-item self-screening questionnaire for depression
and anxiety in patients with physical health problems
and the two 7-item subscales measure how the respond-
ent has been feeling in the past week. The scale scores
range from 0 to 21, with higher scores indicating greater
levels of anxious or depressed mood. A score of 0–7 on
either subscale is regarded as being in the ‘normal’
range, a score of 8–10 is suggestive of the presence of
moderate levels of anxiety or depression, and a score of
11 or above indicates ‘caseness’, a high likelihood that a
person would be diagnosed with clinical anxiety or clin-
ical depression. A systematic review of the HADS has
confirmed the factor structure and found the cut-off
points to be valid against clinical interviews [22]. This
tool has demonstrated high internal consistency (r = 0.76
to 0.41 for anxiety scale items and r = 0.60 to 0.30 for
depression scale items) and good reliability [23].
Illness beliefs Illness perceptions are cognitive repre-
sentations or beliefs that a patient has about their illness.
These concepts will be measured using the revised Ill-
ness Perceptions Questionnaire Revised (IPQ-R; [24])
that assesses each of the components of illness represen-
tations (Table 1).
Total scores on the illness identity subscale range from
0 to 14 and higher scores represent strong beliefs about
the number of symptoms attributed to their condition.
In order to increase the face validity of this subscale four
blepharospasm and hemifacial spasm symptoms were
added to the identity scale: (1) frequent blinking, (2) irri-
tation of the eye, (3) uncontrollable eye closure and, and
(4) muscle twitching around the face and/or eye; bring-
ing the maximum score up to 18. Total scores range
from 6 to 30 for the consequences, timeline acute/
chronic, emotional representation and personal control
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subscales and 5–25 for treatment control and illness co-
herence and 5–20 for timeline cyclical. High scores rep-
resent strongly held beliefs about their condition. The
subscales have been found to possess good internal
consistency [25]. Cause is assessed in 18 items which are
analysed in three groupings, causes relating to psycho-
logical attributions, risk factors and immunity. Each of
these subscales possesses good internal consistency ran-
ging from 0.67 for immunity to 0.86 for the psycho-
logical attribution subscale [25]. Participants are also
asked to rank the three most important factors that they
believe caused their illness.
Treatment beliefs Beliefs about botulinum toxin will be
measured using the Treatment Representations Inven-
tory (TRI; [21]); a 27-item measure, consisting of four
scales measure on a 5-point Likert agreement scale.
Scales include treatment-value, treatment-concerns,
decision-satisfaction and cure. Scales demonstrate good
internal consistency (Cronbach’s alpha: 0.78, 0.77, 0.80
and 0.75 respectively).
Confidence Confidence in the service will be assessed
using a 10-cm visual analogue scale (VAS), as in other
evaluations of patient-initiated services [24, 26, 27]. Par-
ticipants will be asked ‘How confident are you that if
you required treatment this system of care would be able
to support you?’, ranging from ‘not at all confident’ to
‘completely confident’. Individual side effects will also be
recorded at each clinic visit by the treating health-
care professional along with a subjective assessment
of the duration of beneficial effect of their last treat-
ment, in weeks.
Acceptability Acceptability of the new patient-initiated
service and standard care will be measured using the
seven-item Acceptability Questionnaire [28]. Responses
are on a Likert scale from 1 to 5 and response labels
vary depending on the item, for example, ‘How fair do
you feel this system has been?’ has the response options
‘not at all fair’ (1) to ‘very fair’ (5). The questionnaire will
be validated using established methods once all data has
been collected.
Health-care usage Use of health and social care services
will be estimated using a brief version of the Client Ser-
vice Receipt Inventory (CSRI; [29]) completed by a com-
bination of self-report and electronic patient records
(EPR). The CSRI has been validated and widely
employed in previous studies, particularly in the mental
health setting [29] and has been found to be a suitable
tool for use with patients experiencing psychological dis-
tress [30].
Cost-effectiveness The impact of the service on direct
and indirect costs will be estimated at the end of the
trial period using this brief CSRI [29]. This data will be
collected by the research nurse at the 9- month follow-
up visit, who will ask participants to report which ser-
vices they have accessed in the past 9 months. This in-
formation will be cross-referenced with each patient’s
hospital notes to minimise recall bias. The accurate col-
lection of resource-use data is commonly a challenge in
economic evaluation and the method of comparing pa-
tient self-report to healthcare records has been used in
recent research [31]. Unit costs of healthcare resources
will be derived from the NHS trust where possible. For
sensitivity analysis, and/or where there is an absence of
costs available locally, national unit costs that are judged
representative of local costs will be obtained from na-
tional sources, such as NHS Commissioning or NHS
England. Costs associated with the different resources
and services will be reported as part of this economic
evaluation. To calculate the costs, we will look at: (1) re-
source use in primary care, including an examination of
total botulinum toxin used, visits to the GP, and other
services, (2) resource use in secondary care including at-
tendance at accident and emergency clinics (A&E), (3)
resource use from specialty services, (4) intervention
costs and costs of treatment as usual for comparison, (5)
resources associated with any admissions will be re-
corded and totalled with all the previously identified re-
sources, to calculate a total cost to the health service
overall, (6) resource use in social care including social
worker and community psychiatric nurse, and (7) out-
of-pocket costs to the individual such as visual aids and
travel to appointments. Out-of-pocket costs, including
the cost of visual aids, to the individual will also be
Table 1 Definitions of the Illness Perceptions Questionnaire
Revised (IPQ-R) subscales
Subscale A belief…..
Cause …about the cause of my illness
Identity …about the number of symptoms attributable
to their condition
Time (acute/chronic) …about the duration of the condition
Consequences …that their condition will have serious
consequences
Personal control …in one’s ability to personally influence the
outcome of their condition
Treatment control …that medical treatments will be effective in
controlling their condition
Illness coherence …that condition ‘makes sense’




…that the condition is emotionally distressing
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recorded at baseline. A fuller description of the methods
used to conduct the cost-effectiveness analysis is de-
scribed in the statistical methods section.
Frequency of outpatient visits The length of time be-
tween visits to the nurse-led clinic will be recorded (in
days) for participants in both arms of the trial. In the
patient-initiated treatment group the reasons for initiat-
ing a consultation will be recorded at the time of initiat-
ing the appointment.
Adverse effects The frequency of adverse events includ-
ing ptosis, double or blurred vision, tearing, hematoma
and foreign body sensation will also be recorded at each
clinic visit as either present or absent. Patients will also
be followed up 2 weeks after each visit in which they re-
ceive botulinum toxin treatment to assess any adverse
events.
Procedures
Invitation letters will be sent to eligible patients 2 weeks
prior to their outpatient appointment in the nurse-led
botulinum toxin clinic by the trial co-ordinator. On the
day of the appointment the patient will be approached
by the research fellow to participate in the study. Those
who agree will be consented into the trial by the re-
search fellow. Qualitative data will be collected on rea-
sons for refusal. Baseline assessment questionnaires will
be given to participants consenting to take part in the
study with a freepost envelope for return, all subsequent
follow-up self-report questionnaires will be sent to the
participants’ home also with a freepost envelope for re-
turn. Participants who do not return questionnaires
within 2 weeks will be contacted by telephone. If partici-
pants do not respond to one follow-up telephone call
and one letter, and there is no evidence that the patient
has moved, it will be considered that they no longer
wish to take part in the trial and they will not be sent
further questionnaires. They will continue in the trial on
the basis that clinical and cost-effectiveness data can still
be collected and an intention-to-treat analysis (ITT) will
be performed. Participants in the intervention trial arm
who no longer wish to take part in the trial but are
happy to continue to complete questionnaires will also
be included in the ITT analysis.
Disease severity and function will be assessed at base-
line and then at each clinic visit by the treating health-
care professionals and again 2 weeks after treatment via
telephone by the research fellow.
Participants in the intervention group who have agreed
to be contacted about an interview to assess acceptabil-
ity of the new service will be followed up with a tele-
phone call by a research assistant to arrange a time and
place for the interview. Participants will be interviewed
after their 9-month participation in the trial has ended.
Data monitoring
Data collection will be monitored by an external moni-
toring agency experienced in NHS Research and Devel-
opment (R&D) processes. The following will be
monitored: collection of the JRS and BSDI© at each time
point, identification of adverse events not recorded and
the appropriate recording of telephone calls from pa-
tients requesting appointments. The first monitoring
visit will take place shortly after recruitment commen-
cing to identify issues early into the study and resolving
these promptly. A single further follow-up visit will be
scheduled to take place 6 months after the first.
Patient safety
Patient safety will be monitored by the specialist re-
search nurse treating patients and the research fellow.
Participants will be automatically booked back into the
nurse-led botulinum toxin clinic at the end of the trial
period by the trial co-ordinator. Reasons for not initiat-
ing treatment during participation in the trial will be re-
corded for any patients who have not attended for the
full duration and all patients will continue to receive
standard care.
Sample size
Sample size for multilevel modelling (MLM) was esti-
mated by simulating a range of scenarios using the soft-
ware Power and Precision™ (Version 4.1; [32]). Using a
large ICC of 0.3 [33], time as nested within participants,
and setting power at 80 %, it was estimated that between
92 and 230 participants would be required with small to
medium effects (Table 2). Based on a 79 % completion
rate [9] this would mean that between 112 (56 per
group) and 278 (139 per group) will need to be con-
sented into the trial.
Table 2 Sample size estimation based on four scenarios with small to medium effect sizes
Scenario Effect size (d) ICC Standard care Intervention Time points Alpha Tails Power
Scenario 1 0.25 0.3 115 115 4 0.05 2 0.80
Scenario 2 0.3 0.3 80 80 4 0.05 2 0.80
Scenario 3 0.35 0.3 59 59 4 0.05 2 0.80
Scenario 4 0.4 0.3 46 46 4 0.05 2 0.81
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The qualitative study assessing acceptability of the new
service aims to recruit an initial sample of 10 partici-
pants with a stopping criterion of a further three inter-
views to confirm that data saturation has been achieved
[34]. Data saturation is defined as the emergence of no
new themes in relation to the research question.
Statistical methods
All quantitative analyses will be undertaken in IBM SPSS
Statistics Version 22.0 by the research fellow and trial
statistician.
Changes over time
In order to explore stability in the primary outcome
measures over the treatment period, and change in satis-
faction, quality of life, mood and illness and treatment
beliefs, multilevel models (MLM) will be employed.
Time will be nested within participants and to check the
assumption that scores within a participant are highly
correlated, the first MLM will include no predictors and
a scaled identity covariance type for both level 1 and
level 2 in order to calculate the intraclass correlation co-
efficient (ICC). Models will be fitted with a first order
autoregressive (AR1) covariance structure. Restricted Es-
timate Maximum Likelihood (REML) methods will be
used as these are preferred for smaller samples [35].
Trial arm (0 = control, 1 = intervention), time (0, 1, 2)
and the interaction between trial arm and time will be
entered as fixed effects in each model, with participant
identification number as a random effect. A significant
interaction term will be interpreted as evidence for dif-
ferential treatment effectiveness. Pairwise comparisons
will be performed in order to establish where the signifi-
cant differences lie, using estimated marginal means and
standard errors. Standardised adjusted effect sizes for
group differences at each time point will be calculated
using Hedges’ g along with 99 % confidence intervals
(as p < 0.01) using the formula provided by Turner
and Bernard [36]. Hedges’ g includes a correction fac-
tor for small samples which, if absent, may lead to a less
accurate and upwardly biased effect size. These effect sizes
are interpreted in the same way as Cohen’s d [37] (small =
0.20, medium= 0.50, large = 0.80).
Difference in mean costs
Costs of services used by each participant will be esti-
mated from the quantities of each type of resource used,
multiplied by the unit cost. A total cost per case per pa-
tient will be calculated based on all of the above which
in turn will allow for an average cost per case per trial
arm for treatment and the control group, presented with
rates of significance of difference between arms.
A cost utility analysis will be performed combining the
cost data with the primary clinical outcome measures
for functional disability (BSDI©) and disease severity
(JRS). A further cost utility analysis will be performed on
quality of life (CDQ-24), a secondary clinical outcome
measure for the trial.
Cost per unit of therapeutic change, whether this be
clinical improvement, reduced disability, change in qual-
ity of life or increased patient satisfaction will be
calculated.
As part of the economic evaluation, non-parametric
bootstrapping will be used to develop confidence intervals
around the incremental cost-effectiveness ratio based on
costs and associated effectiveness data (functional disabil-
ity, disease severity, quality of life and patient satisfaction).
This process also generates acceptability curves to illus-
trate the uncertainty associated with the estimate of costs
and effects combined and (probabilistic) estimates of af-
fordability given potentially different decision-maker cost
thresholds.
Acceptability of the service
The questionnaire used to capture participants’ views of
acceptability of the intervention will be validated after
data has been collected. Recognised and widely
employed questionnaire validation methods will be used
to assess for internal consistency, concurrent, discrimin-
ant and predictive validity.
Qualitative analysis
The semi-structured interviews will be digitally recorded
with the participant’s consent and transcribed verbatim
by a professional transcribing company. Any information
which could identify a participant will be anonymised.
The data generated from these semi-structured inter-
views will be analysed using framework analysis [38]; a
method for identifying, analysing and reporting patterns
within data, using NVivo Software (Version 10) [39].
This method allows themes to be identified across a
dataset and is appropriate for use in studies with a fo-
cused research question, as in the case of this study.
Framework analysis involves searching across a data set
to find the key issues and themes following five steps:
(1) familiarising yourself with your data, (2) identifying a
thematic framework, (3) indexing, (4) charting, and (5)
mapping and interpretation [38].
In addition to this six-phase process, four validity cri-
teria will be employed: (1) an audit trial which involves
detailed quotes from the participant’s transcripts to pro-
vide evidence for the interpretation offered, (2) a peer
panel: an auditor will be asked to go through randomly
selected sections of transcripts to confirm the pattern of
analysis, (3) the researchers will attempt to recognise
their own values, interests and views and the role that
they may play in their understanding of the transcripts.
Doing this can help the reader to interpret the
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researcher’s data and analysis. A reflective diary will be
kept by the researcher, where notes are kept about initial
thoughts and feelings, the main points that arise in the
interview and any factors that the researcher felt influ-
enced the interviewee. These will be taken into account
throughout the analysis process, and (4) an independent
audit: an independent auditor familiar with framework
analysis will be asked to check the validity of the ‘final
report’.
Research ethics approval
The trial has received full NHS Research Ethics Com-
mittee (REC) approval (REC reference: 15/LO/0439)
from London – Queen Square REC. Patients must pro-
vide written informed consent to take part in the study.
Any data collected from the study participants will be
anonymised and no identifying information will be used
in publications.
Dissemination
The study results will be disseminated to relevant
healthcare professionals via appropriate pre-identified
healthcare journals. The results will also be disseminated
to the public through the publicly available clinical trials
database clinicaltrials.gov.uk. The results will also be
presented at relevant scientific conferences.
Patient and public involvement
Two patients with blepharospasm and hemifacial spasm
have been invited to join the study management group.
These patient members have provided valuable feedback
on study materials (e.g. information sheets, consent
forms) and acceptability of study measures and will help
with interpretation and dissemination of the research
findings. The trial will also be presented at a Blepharo-
spasm Patient Study Day organised by MEH in Novem-
ber 2015 to gain feedback from patients about the
acceptability of the intervention from their perspective.
Discussion
Given the shift away from the paternalistic model of
healthcare, it is important to provide patients with the
tools to take a more active role in knowing and man-
aging their health. This trial will enable patients with
dystonia to control the timing of their appointments and
ultimately manage their own symptoms. This study is
the first RCT to assess the effectiveness of patient-
initiated treatment model for patients with blepharo-
spasm and hemifacial spasm, whilst improving patient
satisfaction with care, in comparison to treatment as
usual.
The evaluation of this new service will use a rigorous
mixed-methods design to explore whether empowering
patients to initiate their own appointments allows for a
more stable pattern of disease severity and symptoms,
whilst improving patient satisfaction and acceptability
with their care, and quality of life. The costs of deliver-
ing the service, and the impact it has on other healthcare
use will be measured and compared in relation to con-
trol participants. The authors do not anticipate any
safety concerns for the trial; however, appropriate risk
assessment and monitoring procedures have been
implemented.
If the new model is shown to be effective in maintain-
ing a more stable pattern of disease severity, symptoms
and disability, and at the same time being satisfactory
and acceptable to patients, whilst being cost-effective,
this will have significant implications for service organ-
isation across the NHS.
Trial status
Patient recruitment for this trial began in August 2015.
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